Published online May 16, 2024. doi: 10.12998/wjcc.v12.i14.2431
Revised: March 14, 2024
Accepted: April 2, 2024
Published online: May 16, 2024
Processing time: 101 Days and 18.9 Hours
Cronkhite-Canada syndrome (CCS) is a rare disease of unknown etiology. The optimal treatment for CCS remains unknown. Treatment with corticosteroids is considered the mainstay treatment because of its high efficacy, but the therapeutic strategy for steroid-resistant CCS is not yet established.
This is the case of an 81-year-old woman who was diagnosed with CCS. Given her severe diarrhea, nausea, vomiting, and hypoproteinemia, hormone therapy (40 mg/d) was administered, and the symptoms improved within 1 wk. After 3 mo, the patient had no obvious symptoms. The polyps were significantly reduced on review gastroscopy and colonoscopy, thus hormone reduction gradually began. The hormone level was maintained at 10 mg/d after 6 mo. Despite the age of the patient and the side effects of hormones, the patient had no obvious discomfort. However, hormone drugs were discontinued, and mesalazine was administered orally at 3 g/d. The patient's symptoms continued to improve after a follow-up of 5 years.
Corticosteroids and mesalazine are potential treatment options for CCS.
Core Tip: Cronkhite-Canada syndrome (CCS) is a rare disease of unknown etiology. The optimal treatment for CCS remains unknown. Treatment with corticosteroids is considered the mainstay treatment because of its high efficacy, but the therapeutic strategy for steroid-resistant CCS is not yet established. The current report describes a case of CCS wherein after the initial therapy with corticosteroids, gastrointestinal symptoms were resolved and polyps were significantly reduced. This was followed by mesalazine monotherapy, which led to long-lasting remission. Thus, corticosteroids and mesalazine are potential treatment options for CCS.